Lakewood-Amedex Reports Nu-3 Activity Against Drug-Resistant Bacteria in Laboratory Study

• Lakewood-Amedex Biotherapeutics will present Nu-3 antimicrobial research at IDWeek 2026 on October 22, 2026.
• Laboratory findings showed rapid activity against resistant bacteria, with a low potential for resistance development.
• Nu-3 is undergoing a Phase 2a trial as a topical treatment for mildly infected diabetic foot ulcers.
• Topline trial results are expected in the first quarter of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakewood-Amedex Biotherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY77233) on October 21, 2026, and is solely responsible for the information contained therein.